Professional Background

At the U.S. National Institutes of Health, Dr. Elsafy held senior medical leadership roles overseeing safety and benefit–risk strategy for national and global public health initiatives. His portfolio included biodefense and emerging infectious disease programs addressing COVID-19, Ebola, Anthrax, pandemic influenza, tuberculosis, malaria, and other priority pathogens. In the biotechnology sector, he has built and led global pharmacovigilance infrastructures, chaired Safety Management and Monitoring Committees, and directed signal detection, risk management, and inspection readiness activities for multi-asset pipelines, including lung cancer and solid tumor programs.

Core Expertise

• Global pharmacovigilance systems, safety governance, and risk management
• Biodefense and emerging infectious disease program oversight
• Oncology safety strategy and translational integration
• Regulatory strategy, aggregate safety reporting, and health authority engagement

Career Highlights

• Directed safety oversight for federally sponsored programs targeting multiple high-consequence infectious threats.
• Completed advanced translational oncology training at the National Cancer Institute and led safety strategy for lung cancer and solid tumor development programs.
• Established and scaled global safety organizations integrating signal detection, regulatory strategy, and inspection-ready quality systems.
• Led cross-functional crisis responses and regulatory interactions during complex safety evaluations and high-risk milestones.

Education & Clinical Training

• Master of Science (General Surgery)
• Medical Degree (M.B., B.Ch.)
• Advanced Translational Oncology Training — National Cancer Institute
• Clinical Pharmacology and Regulatory Science training

Therapeutic Focus